AI Article Synopsis
- - This study aimed to compare the ocular complications in patients with Stevens Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) treated with either systemic IVIG or Ciclosporin (CsA) from 2011 to 2017.
- - A total of 18 patients were analyzed; while the acute ocular severity was similar for both treatment groups, those receiving CsA showed a trend towards worse chronic complications and a higher incidence of severe corneal involvement compared to the IVIG group.
- - The findings suggest that CsA may lead to worse ocular outcomes in SJS/TEN patients than IVIG, but further research with larger sample sizes is needed to validate these results.
Article Abstract
Background/aim: To evaluate differences in ocular complications of Stevens Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) patients receiving either systemic IVIG or Ciclosporin (CsA) as initial treatments.
Methods: Retrospective review of consecutive patients admitted for SJS/TEN at the Singapore General Hospital (SGH) from 2011 to 2017 who received either IVIG or Ciclosporin at the onset of the disease and had ophthalmological follow-up of at least 6 months were included. Acute ocular severity of SJS/TEN was graded using the Gregory grading score; chronic ocular complications were graded using the Sotozono system.
Results: A total of 18 subjects were included for analysis, with eight in the IVIG group and 10 in the CsA group. There were no significant differences in acute Gregory severity grading between the two groups. The CsA group had a trend towards worse overall chronic Sotozono grading scores compared to the IVIG group (median [IQR]: 2 [0-3] vs. 1 [0-6.5], = 0.27), with a higher incidence of acute severe cornea involvement (60% vs. 25%, = 0.93) and chronic corneal and eyelid involvement in the former than the latter. SJS/TEN patients with worse acute ocular involvement were more likely to have TEN and perianal mucosal involvement (50% vs. 0, = 0.01).
Conclusion: Compared to those who received IVIG, SJS/TEN patients who received CsA at the acute disease stage, seemed to have worse acute corneal and chronic corneal and eyelid complications. Larger studies are needed to confirm this finding.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368074 | PMC |
| http://dx.doi.org/10.3389/fmed.2024.1398506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulation of innate immune response by miRNAs up-regulated in Stevens-Johnson syndrome with severe ocular complications.
Sci Rep
January 2025
Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji, Kawaramachi, Kamigyoku, Kyoto, 602-0841, Japan.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous disorders characterized by extensive tissue necrosis; they are often accompanied by severe ocular complications (SOC). The regulatory role of microRNAs (miRNAs) in modulating immune responses in SJS/TEN is not fully understood, particularly in relation to chronic SOC. We explored the expression profiles of specific miRNAs and their potential impact on the regulation of key innate immune genes in patients with SJS/TEN with SOC.
View Article and Find Full Text PDFClinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis.
Invest New Drugs
January 2025
College of Pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
The understanding of pembrolizumab-induced Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN) primarily derives from case reports, leaving specific clinical features largely unknown. This study aims to investigate the clinical characteristics associated with pembrolizumab-induced SJS/TEN and to encourage the judicious use of pembrolizumab. Retrieve reports on pembrolizumab induced SJS/TEN before September 30, 2024 for retrospective analysis.
View Article and Find Full Text PDFImmune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade.
Nat Commun
December 2024
Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
Immune checkpoint inhibitors (ICI) represent new anticancer agents and have been used worldwide. However, ICI can potentially induce life-threatening severe cutaneous adverse reaction (SCAR), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hindering continuous ICI therapy. We examine 6 cohorts including 25 ICI-induced SJS/TEN patients and conduct single-cell RNA sequencing (scRNA-seq) analysis, which shows overexpression of macrophage-derived CXCL10 that recruits CXCR3 cytotoxic T lymphocytes (CTL) in blister cells from ICI-SJS/TEN skin lesions.
View Article and Find Full Text PDFCutaneous Adverse Drug Reactions to Antiseizure Medications.
J Epilepsy Res
December 2024
Department of Dermatology, National Institute of Medical Science and Nutrition Salvador Zubiran, Tlalpan, México.
Discontinuation of antiseizure medications (ASMs), primarily prompted by adverse effects, presents a formidable challenge in the management of epilepsy, and impacting up to 25% of patients. This article thoroughly explores the clinical spectrum of cutaneous adverse drug reactions (cADRs) associated with commonly prescribed ASMs. Ranging from mild maculopapular rashes to life-threatening conditions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the diverse manifestations are meticulously detailed.
View Article and Find Full Text PDFSevere Cutaneous Toxicity in A 67-Year-Old Patient with Metastatic Urothelial Carcinoma Undergoing Therapy with Enfortumab Vedotin and Pembrolizumab.
Eur J Case Rep Intern Med
November 2024
Department of Oncology, Cantonal Hospital Baselland, Liestal, Switzerland.
Article Synopsis
- Enfortumab vedotin combined with pembrolizumab (EV+P) shows effectiveness in treating metastatic urothelial carcinoma, but can lead to severe skin reactions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
- A case is presented of a 67-year-old man who developed SJS/TEN overlap after EV+P therapy, demonstrating the importance of recognizing and treating severe skin toxicities early in patients with additional health issues.
- Effective management requires quick action with steroids and a multidisciplinary approach, alongside vigilant monitoring and reporting of adverse effects to enhance patient safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!